Get the Stockscreener App
1.395
1.09%
0.015
After Hours:
1.40
0.005
+0.36%
Theriva Biologics Inc stock is traded at $1.395, with a volume of 22,420.
It is up +1.09% in the last 24 hours and up +29.17% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$1.38
Open:
$1.38
24h Volume:
22,420
Relative Volume:
0.44
Market Cap:
$3.92M
Revenue:
-
Net Income/Loss:
$-18.35M
P/E Ratio:
-1.2026
EPS:
-1.16
Net Cash Flow:
$-19.20M
1W Performance:
-1.06%
1M Performance:
+29.17%
6M Performance:
-29.19%
1Y Performance:
-99.45%
1-Day Range:
$1.3201
$1.465
1-Week Range:
$1.29
$1.465
52-Week Range:
$0.9563
$306.94
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
1.395 | 3.92M | 0 | -18.35M | -19.20M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Theriva Biologics Inc Stock (TOVX) Latest News
Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Up 6.8% – Should You Buy? - Defense World
Theriva Biologics Announces Presentation of Data from the - GlobeNewswire
Major Clinical Trial Update: Theriva's SYN-004 Shows Promise in Transplant PatientsKey Data Revealed - Stock Titan
Synthetic Biologics stock plunges to 52-week low at $1.02 - Investing.com Australia
Synthetic Biologics stock plunges to 52-week low at $1.02 By Investing.com - Investing.com South Africa
Theriva Biologics Completes Enrollment For VIRAGE Trial, Topline Data Expected In Q2 2025 - Nasdaq
Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Ad - GlobeNewswire
Cancer Drug Breakthrough: Independent Committee Confirms Positive Safety Data in Phase 2b Pancreatic Trial - Stock Titan
Theriva Biologics (NYSEAMERICAN:TOVX) Shares Down 1.4% – Should You Sell? - Defense World
Theriva Biologics to Present at the CAGLA NeauxCancer 2025 Conference in New Orleans - Nasdaq
Theriva™ Biologics to Present at the 2025 NeauxCancer Conference - GlobeNewswire
Theriva Biologics Reports 2024 Financial Results and Progress - TipRanks
Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results - The Manila Times
Can Theriva's PDAC Trial Success and FDA Fast Track Save Its Dwindling Cash Position? - StockTitan
Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual - The Manila Times
Cancer Therapeutics Company Theriva Sets Key Investor Presentation DateWhat to Expect - StockTitan
Theriva Biologics Inc Inc. (TOVX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
US Stocks To Open Higher On Shortened Trading Day: Santa Claus Rally Period Officially Begins, Says Analyst - Benzinga
Why Carbon Revolution Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket - Benzinga
Synthetic Biologics stock hits 52-week low at $1.21 - Investing.com India
Synthetic Biologics stock hits 52-week low at $1.21 By Investing.com - Investing.com UK
Theriva Biologics outlines Phase 3 study for cancer drug By Investing.com - Investing.com Canada
Theriva™ Biologics Announces U.S. FDA Guidance on Design of - GlobeNewswire
Theriva Biologics Gets FDA Guidance on VCN-01 Phase 3 Trial Design for Pancreatic Cancer Treatment - StockTitan
Synthetic Biologics stock hits 52-week low at $1.24 By Investing.com - Investing.com South Africa
Synthetic Biologics stock hits 52-week low at $1.24 - Investing.com
Maxim Group Has Lowered Expectations for Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price - Defense World
Theriva Biologics Highlights Key Achievements in Q3 2024 - TipRanks
Theriva Biologics: Q3 Earnings Snapshot - Houston Chronicle
Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results - GlobeNewswire
Theriva Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
What's Going On With Theriva Biologics Stock Friday? - MSN
Theriva Biologics Expands Stock Plans and Share Authority - TipRanks
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant - GlobeNewswire
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma - Yahoo Finance
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - The Globe and Mail
Synthetic Biologics stock plunges to 52-week low of $1.24 - Investing.com
Theriva Biologics dips 11%, prices 2.5M equity offering - MSN
Theriva Biologics Announces Pricing of $2.5 Million Public Offering - GlobeNewswire
Synthetic Biologics stock plunges to 52-week low of $2.66 - Investing.com
Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer - Yahoo Finance
Theriva™ Biologics Awarded Manufacturing Funding from the - GlobeNewswire
Theriva Biologics (TOVX) Is Making Noise With a Promising Pipeline - Nasdaq
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket - Benzinga
What's Going On With Theriva Biologics Stock? - Benzinga
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Cap:
|
Volume (24h):